Patients with Crohn's disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine

Chang Kyun Lee, Hyun Soo Kim, Byong Duk Ye, Kang Moon Lee, You Sun Kim, Sang Youl Rhee, Hyo Jong Kim, Suk Kyun Yang, Won Moon, Ja Seol Koo, Suck Ho Lee, Geom Seog Seo, Soo Jung Park, Chang Hwan Choi, Sung Ae Jung, Sung Noh Hong, Jong Pil Im, Eun Soo Kim

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background/aims: The effect of immunosuppressants on the efficacy of a variety of vaccines is a controversial issue in patients with inflammatory bowel disease (IBD). In this study we determined whether specific immunosuppressants impair the serological response to the standard 23-valent pneumococcal polysaccharide vaccine (PPSV23) in a large cohort of patients with Crohn's disease (CD). Methods: This was a multi-center, prospective observational study of adult patients with CD at 15 academic teaching hospitals in Korea. The study population received one intramuscular injection of PPSV23. Anti-pneumococcal IgG antibody titers were measured by immunoassay prior to and 4. weeks after vaccination. All vaccination-related adverse events and the effect of the vaccine on disease activity were also evaluated. Results: The overall serological response rate was 67.5% (133/197). The serological response rate was significantly lower in patients on anti-tumor necrosis factor (anti-TNF) therapy (50.0% on anti-TNF alone 58.0% on anti-TNF combined with an immunomodulator, IM) than patients on 5-aminosalicylate (78.4%; all P-values vs. 5-aminosalicylate. <. 0.05); 45.6% (41/90) of patients on anti-TNF therapy were not protected against PPSV23. IM did not affect the immunologic response to the vaccine. Female gender and anti-TNF therapy were significant predictors of non-response to the vaccine (odds ratio [OR] 2.316, P= 0.015; OR 2.582, P= 0.048, respectively). Vaccination was generally safe and tolerated by all patients. Conclusions: Patients with CD on anti-TNF therapy are at significant risk of an inadequate response to PPSV23. The pneumococcal vaccination strategy should be optimized for patients with CD on anti-TNF therapy.

Original languageEnglish
Pages (from-to)384-391
Number of pages8
JournalJournal of Crohn's and Colitis
Volume8
Issue number5
DOIs
Publication statusPublished - 2014 May 1

Fingerprint

Pneumococcal Vaccines
Crohn Disease
Tumor Necrosis Factor-alpha
Vaccination
Vaccines
Mesalamine
Therapeutics
Immunosuppressive Agents
Odds Ratio
Intramuscular Injections
Immunologic Factors
Korea
Inflammatory Bowel Diseases
Immunoassay
Teaching Hospitals
Observational Studies
Prospective Studies
Pneumovax 23
Antibodies

Keywords

  • Crohn's disease
  • Immunosuppressive agents
  • Inflammatory bowel disease
  • Pneumococcal vaccine

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Patients with Crohn's disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine. / Lee, Chang Kyun; Kim, Hyun Soo; Ye, Byong Duk; Lee, Kang Moon; Kim, You Sun; Rhee, Sang Youl; Kim, Hyo Jong; Yang, Suk Kyun; Moon, Won; Koo, Ja Seol; Lee, Suck Ho; Seo, Geom Seog; Park, Soo Jung; Choi, Chang Hwan; Jung, Sung Ae; Hong, Sung Noh; Im, Jong Pil; Kim, Eun Soo.

In: Journal of Crohn's and Colitis, Vol. 8, No. 5, 01.05.2014, p. 384-391.

Research output: Contribution to journalArticle

Lee, CK, Kim, HS, Ye, BD, Lee, KM, Kim, YS, Rhee, SY, Kim, HJ, Yang, SK, Moon, W, Koo, JS, Lee, SH, Seo, GS, Park, SJ, Choi, CH, Jung, SA, Hong, SN, Im, JP & Kim, ES 2014, 'Patients with Crohn's disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine', Journal of Crohn's and Colitis, vol. 8, no. 5, pp. 384-391. https://doi.org/10.1016/j.crohns.2013.09.022
Lee, Chang Kyun ; Kim, Hyun Soo ; Ye, Byong Duk ; Lee, Kang Moon ; Kim, You Sun ; Rhee, Sang Youl ; Kim, Hyo Jong ; Yang, Suk Kyun ; Moon, Won ; Koo, Ja Seol ; Lee, Suck Ho ; Seo, Geom Seog ; Park, Soo Jung ; Choi, Chang Hwan ; Jung, Sung Ae ; Hong, Sung Noh ; Im, Jong Pil ; Kim, Eun Soo. / Patients with Crohn's disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine. In: Journal of Crohn's and Colitis. 2014 ; Vol. 8, No. 5. pp. 384-391.
@article{4b7174ccc9e24daba19a0462e6214934,
title = "Patients with Crohn's disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine",
abstract = "Background/aims: The effect of immunosuppressants on the efficacy of a variety of vaccines is a controversial issue in patients with inflammatory bowel disease (IBD). In this study we determined whether specific immunosuppressants impair the serological response to the standard 23-valent pneumococcal polysaccharide vaccine (PPSV23) in a large cohort of patients with Crohn's disease (CD). Methods: This was a multi-center, prospective observational study of adult patients with CD at 15 academic teaching hospitals in Korea. The study population received one intramuscular injection of PPSV23. Anti-pneumococcal IgG antibody titers were measured by immunoassay prior to and 4. weeks after vaccination. All vaccination-related adverse events and the effect of the vaccine on disease activity were also evaluated. Results: The overall serological response rate was 67.5{\%} (133/197). The serological response rate was significantly lower in patients on anti-tumor necrosis factor (anti-TNF) therapy (50.0{\%} on anti-TNF alone 58.0{\%} on anti-TNF combined with an immunomodulator, IM) than patients on 5-aminosalicylate (78.4{\%}; all P-values vs. 5-aminosalicylate. <. 0.05); 45.6{\%} (41/90) of patients on anti-TNF therapy were not protected against PPSV23. IM did not affect the immunologic response to the vaccine. Female gender and anti-TNF therapy were significant predictors of non-response to the vaccine (odds ratio [OR] 2.316, P= 0.015; OR 2.582, P= 0.048, respectively). Vaccination was generally safe and tolerated by all patients. Conclusions: Patients with CD on anti-TNF therapy are at significant risk of an inadequate response to PPSV23. The pneumococcal vaccination strategy should be optimized for patients with CD on anti-TNF therapy.",
keywords = "Crohn's disease, Immunosuppressive agents, Inflammatory bowel disease, Pneumococcal vaccine",
author = "Lee, {Chang Kyun} and Kim, {Hyun Soo} and Ye, {Byong Duk} and Lee, {Kang Moon} and Kim, {You Sun} and Rhee, {Sang Youl} and Kim, {Hyo Jong} and Yang, {Suk Kyun} and Won Moon and Koo, {Ja Seol} and Lee, {Suck Ho} and Seo, {Geom Seog} and Park, {Soo Jung} and Choi, {Chang Hwan} and Jung, {Sung Ae} and Hong, {Sung Noh} and Im, {Jong Pil} and Kim, {Eun Soo}",
year = "2014",
month = "5",
day = "1",
doi = "10.1016/j.crohns.2013.09.022",
language = "English",
volume = "8",
pages = "384--391",
journal = "Journal of Crohn's and Colitis",
issn = "1873-9946",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Patients with Crohn's disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine

AU - Lee, Chang Kyun

AU - Kim, Hyun Soo

AU - Ye, Byong Duk

AU - Lee, Kang Moon

AU - Kim, You Sun

AU - Rhee, Sang Youl

AU - Kim, Hyo Jong

AU - Yang, Suk Kyun

AU - Moon, Won

AU - Koo, Ja Seol

AU - Lee, Suck Ho

AU - Seo, Geom Seog

AU - Park, Soo Jung

AU - Choi, Chang Hwan

AU - Jung, Sung Ae

AU - Hong, Sung Noh

AU - Im, Jong Pil

AU - Kim, Eun Soo

PY - 2014/5/1

Y1 - 2014/5/1

N2 - Background/aims: The effect of immunosuppressants on the efficacy of a variety of vaccines is a controversial issue in patients with inflammatory bowel disease (IBD). In this study we determined whether specific immunosuppressants impair the serological response to the standard 23-valent pneumococcal polysaccharide vaccine (PPSV23) in a large cohort of patients with Crohn's disease (CD). Methods: This was a multi-center, prospective observational study of adult patients with CD at 15 academic teaching hospitals in Korea. The study population received one intramuscular injection of PPSV23. Anti-pneumococcal IgG antibody titers were measured by immunoassay prior to and 4. weeks after vaccination. All vaccination-related adverse events and the effect of the vaccine on disease activity were also evaluated. Results: The overall serological response rate was 67.5% (133/197). The serological response rate was significantly lower in patients on anti-tumor necrosis factor (anti-TNF) therapy (50.0% on anti-TNF alone 58.0% on anti-TNF combined with an immunomodulator, IM) than patients on 5-aminosalicylate (78.4%; all P-values vs. 5-aminosalicylate. <. 0.05); 45.6% (41/90) of patients on anti-TNF therapy were not protected against PPSV23. IM did not affect the immunologic response to the vaccine. Female gender and anti-TNF therapy were significant predictors of non-response to the vaccine (odds ratio [OR] 2.316, P= 0.015; OR 2.582, P= 0.048, respectively). Vaccination was generally safe and tolerated by all patients. Conclusions: Patients with CD on anti-TNF therapy are at significant risk of an inadequate response to PPSV23. The pneumococcal vaccination strategy should be optimized for patients with CD on anti-TNF therapy.

AB - Background/aims: The effect of immunosuppressants on the efficacy of a variety of vaccines is a controversial issue in patients with inflammatory bowel disease (IBD). In this study we determined whether specific immunosuppressants impair the serological response to the standard 23-valent pneumococcal polysaccharide vaccine (PPSV23) in a large cohort of patients with Crohn's disease (CD). Methods: This was a multi-center, prospective observational study of adult patients with CD at 15 academic teaching hospitals in Korea. The study population received one intramuscular injection of PPSV23. Anti-pneumococcal IgG antibody titers were measured by immunoassay prior to and 4. weeks after vaccination. All vaccination-related adverse events and the effect of the vaccine on disease activity were also evaluated. Results: The overall serological response rate was 67.5% (133/197). The serological response rate was significantly lower in patients on anti-tumor necrosis factor (anti-TNF) therapy (50.0% on anti-TNF alone 58.0% on anti-TNF combined with an immunomodulator, IM) than patients on 5-aminosalicylate (78.4%; all P-values vs. 5-aminosalicylate. <. 0.05); 45.6% (41/90) of patients on anti-TNF therapy were not protected against PPSV23. IM did not affect the immunologic response to the vaccine. Female gender and anti-TNF therapy were significant predictors of non-response to the vaccine (odds ratio [OR] 2.316, P= 0.015; OR 2.582, P= 0.048, respectively). Vaccination was generally safe and tolerated by all patients. Conclusions: Patients with CD on anti-TNF therapy are at significant risk of an inadequate response to PPSV23. The pneumococcal vaccination strategy should be optimized for patients with CD on anti-TNF therapy.

KW - Crohn's disease

KW - Immunosuppressive agents

KW - Inflammatory bowel disease

KW - Pneumococcal vaccine

UR - http://www.scopus.com/inward/record.url?scp=84897413269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897413269&partnerID=8YFLogxK

U2 - 10.1016/j.crohns.2013.09.022

DO - 10.1016/j.crohns.2013.09.022

M3 - Article

VL - 8

SP - 384

EP - 391

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

SN - 1873-9946

IS - 5

ER -